INTRODUCTION

Life-changing therapies for people living with serious inflammatory diseases

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody® for the treatment of inflammation, to elevate outcomes for patients.

WHAT’S GOING ON

MoonLake news

03/24
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
03/24
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
02/24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
02/24
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
11/23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
10/23
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
10/23
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
10/23
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
09/23
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
08/23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
07/23
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
06/23
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
06/23
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
06/23
MoonLake R&D Day - Phase 2 Results MIRA Trial
06/23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
05/23
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
04/23
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
03/23
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
02/23
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
12/22
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
11/22
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
11/22
We are thrilled to announce that MoonLake has been awarded the European Lifestars Awards - Celebrating Life Science Executives & their partners Lifestars Awards ‘Post-IPO Equity Raise of the Year’ Award in recognition of our successful business combination and fundraising this year.
09/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
07/22
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
05/22
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
05/22
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
04/22
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.
03/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
10/21
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab
08/21
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
07/21
MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO
05/21
MoonLake Immunotherapeutics announces publication in The Lancet
05/21
MoonLake In-licensing and launch
ABOUT US

We go
beyond

We go beyond by bringing unrivalled expertise and experience to innovate the way new treatments are developed for inflammatory diseases.
SCIENCE

We do stellar science

We apply stellar science, sponsoring innovative research work and clinical trials globally, to target inflammatory diseases with a major unmet need where Sonelokimab has the potential to transform patient outcomes.
INVESTOR RELATIONS

We unlock
value

We are unlocking the value of Sonelokimab with our ambitious Phase 2 program across lead indications for hidradenitis suppurativa and psoriatic arthritis.